Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
NovoCure Ltd (NVCR)
NASDAQ:NVCR
Holding NVCR?
Track your performance easily
NVCR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$11.29 - $24.74
Previous Close$16.48
Volume673.96K
Average Volume (3M)1.03M
Market Cap
$1.78B
Enterprise Value$1.51B
Total Cash (Recent Filing)$951.19M
Total Debt (Recent Filing)$675.20M
Price to Earnings (P/E)―
Beta1.77
Next Earnings
Feb 20, 2025EPS Estimate
-$0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.39
Shares Outstanding108,201,434
10 Day Avg. Volume898,653
30 Day Avg. Volume1,034,412
Standard Deviation0.21
R-Squared0.03
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)4.95
Price to Sales (P/S)3.02
Price to Cash Flow (P/CF)41.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.74
Enterprise Value/Gross Profit3.96
Enterprise Value/Ebitda-11.65
Forecast
1Y Price Target
$27.17Price Target Upside61.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
NovoCure News
PremiumCompany Announcements
Novocure’s Q3 2024 Results Highlight Growth and Innovation
PremiumCompany Announcements
NovoCure’s Strong Q3 and Leadership Changes in 2024
PremiumPre-Earnings
Is NVCR a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Market ExpansionThe 2L NSCLC opportunity is potentially much larger than the commercial business in glioblastoma, which could lead to significant sales growth following 2025.
Product LaunchOptune Lua US launch is underway with the first prescription already received since approval, indicating strong potential for sales growth.
Regulatory ApprovalFDA approval of Optune Lua was granted with a favorable label for the treatment of metastatic NSCLC, which is very positive news given the lack of approved therapies in the 2L setting.
Bears Say
Clinical TrialsConcerns are raised about the interpretation of trial results due to many patients having unknown PD-L1 status, potentially confounding results.
Financial PerformanceThe initial launch will be at-risk, resulting in lower gross margins for the near-term until the company is able to file claims for initial sales.
Leadership ChangesThe company has begun an external search for a new CFO.
---
Ownership Overview
1.40% Insiders
31.83% Mutual Funds
25.34% Other Institutional Investors
25.00% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NVCR FAQ
What was NovoCure Ltd’s price range in the past 12 months?
NovoCure Ltd lowest stock price was $11.29 and its highest was $24.73 in the past 12 months.
What is NovoCure Ltd’s market cap?
Currently, no data Available
When is NovoCure Ltd’s upcoming earnings report date?
NovoCure Ltd’s upcoming earnings report date is Feb 20, 2025 which is in 91 days.
How were NovoCure Ltd’s earnings last quarter?
NovoCure Ltd released its earnings results on Oct 30, 2024. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.334 by $0.054.
Is NovoCure Ltd overvalued?
According to Wall Street analysts NovoCure Ltd’s price is currently Undervalued.
Does NovoCure Ltd pay dividends?
NovoCure Ltd does not currently pay dividends.
What is NovoCure Ltd’s EPS estimate?
NovoCure Ltd’s EPS estimate is -$0.35.
How many shares outstanding does NovoCure Ltd have?
NovoCure Ltd has 108,201,430 shares outstanding.
What happened to NovoCure Ltd’s price movement after its last earnings report?
NovoCure Ltd reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.334. Following the earnings report the stock price went up 0.592%.
Which hedge fund is a major shareholder of NovoCure Ltd?
Among the largest hedge funds holding NovoCure Ltd’s share is Coatue Management, LLC. It holds NovoCure Ltd’s shares valued at 10M.
---
NovoCure Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$27.17 (61.15% Upside)
$27.17 (61.15% Upside)
Blogger Sentiment
Bullish
NVCR Sentiment 66%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
33.22%
12-Months-Change
Fundamentals
Return on Equity
-39.70%
Trailing 12-Months
Asset Growth
6.60%
Trailing 12-Months
Company Description
NovoCure Ltd
NovoCure Ltd. develops treatment for tumors. Its platform is called the Tumor Treating Field which used electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
---
NVCR Company Deck
---
NVCR Earnings Call
Q3 2024
0:00 / 0:00
---
NVCR Net revenue Breakdown
68.67% U.S.
11.82% Germany
8.74% Japan
6.22% Other EMEA
4.56% Greater China
---
NVCR Stock 12 Month Forecast
Average Price Target
$27.17
▲(61.15% Upside)
Technical Analysis
Best Analysts Covering NVCR
1 Year
1 Year Success Rate
13/18 ratings generated profit
1 Year Average Return
+9.79%
reiterated a buy rating last month
Copying Larry Biegelsen's trades and holding each position for 1 Year would result in 72.22% of your transactions generating a profit, with an average return of +9.79% per trade.
---